Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Girish Munavalli

MOHS-Micrographic Surgery Charlotte, NC Medical Doctor

NPI 1215910336 CMS profile 100121

1918 Randolph Rd, Suite 550, Charlotte, NC 28207

Open in the dashboard

General payments

$117,940

163 records reported · program years 2019–2025

Research payments

$1,113

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$421,865 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Girish Munavalli of Charlotte, NC is reported in the CMS Open Payments database as having received $117,940 across 163 general payments and $1,113 in research payments paid to them. Separately, studies naming them as principal investigator received $421,865 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,317 9
2025 Research $820 6
2024 General $16,043 21
2023 General $4,573 23
2022 General $21,483 32
2021 General $24,344 20
2020 General $5,193 10
2019 General $39,987 48
2019 Research $293 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Girish Munavalli
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Girish Munavalli were reported at $6,317. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Girish Munavalli MOHS-Micrographic Surgery median Middle half National median
2019 $39,987 $316 $106–$785 $163
2020 $5,193 $162 $68–$412 $114
2021 $24,344 $243 $87–$654 $132
2022 $21,483 $300 $102–$887 $149
2023 $4,573 $364 $125–$1,010 $160
2024 $16,043 $445 $142–$1,108 $164
2025 $6,317 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $19,145 15 payments
  2. Dermira, Inc. $18,072 15 payments
  3. AbbVie, Inc. $15,088 29 payments
  4. Solta Medical, a division of Bausch Health US, LLC $14,604 10 payments
  5. Merz North America, Inc. $9,906 26 payments
  6. Lumenis BE inc $8,766 1 payment
  7. Biofrontera Inc. $6,681 7 payments
  8. Lumenis BE (HK) Limited $5,347 1 payment
  9. STRATA Skin Sciences, Inc. $4,695 9 payments
  10. Lumenis, Inc $3,596 1 payment
  11. Other $12,041 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $67,035 35 payments
  2. Honoraria $19,097 5 payments
  3. Food and Beverage $13,604 103 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,096 3 payments
  5. Travel and Lodging $4,827 11 payments
  6. Education $281 6 payments
Products named General payments · program years 2019–2025
  1. QBREXZA $18,072 15 payments
  2. Xeomin $9,247 15 payments
  3. M22 $8,766 1 payment
  4. Ameluz $6,665 6 payments
  5. BF-RhodoLED $6,665 6 payments
  6. XEPI $5,000 2 payments
  7. XTRAC $4,695 9 payments
  8. BOTOX Facial Aesthetics $2,813 13 payments
  9. WYNZORA $2,580 4 payments
  10. BOTOX Botox Therapeutic $2,400 1 payment
  11. Other $4,951 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $820 6 payments
  2. Biofrontera Inc. $293 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

487

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$3,074

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

3.9%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 256 $1,852
Mupirocin Generic 68 $404
Cefadroxil Generic 23 $295
Ketoconazole Generic 13 $165
Valacyclovir Valacyclovir Hcl Brand 19 $115
Triamcinolone Acetonide Generic 18 $87
Tramadol Hcl Generic 57 $70
Spironolactone Generic 15 $59
Prednisone Generic 18 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$320,494

Of which drugs: $7,660

Medicare patients

438

Average age 75

Services billed

1,550

206 women, 232 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 45%
Ischemic heart disease 26%
Cancer 18%
Atrial fibrillation 17%
Diabetes 15%
Chronic kidney disease 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 23 25 $7,650

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $2,507
$2,507 — —
DUPIXENT
  • GENZYME CORPORATION $51
$51 — —
Winlevi
  • Sun Pharmaceutical Industries Inc. $44
$44 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $28
$28 — —
SKYRIZI
  • AbbVie, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record